Trial ID: | L0447 |
Source ID: | IRCT20140107016123N14
|
Associated Drug: |
Pomegranate
|
Title: |
The effect of pomegranate extract tablet on some of metabolic factor, hepatokines (fetuin A, FGF21), inflammatory biomarkers, anthropometric indices and grade of fatty liver in patients with non-alcoholic fatty Liver disease
|
Acronym: |
--
|
Status: |
Recruiting
|
Study Results: |
No Results Available
|
Results: |
--
|
Conditions: |
Nonalcoholic fatty liver disease (NAFLD). <br>Fatty (change of) liver, not elsewhere classified;K76.0
|
Interventions: |
Intervention 1: Intervention group: Pomegranate extract tablet 225 mg twice daily for 12 weeks. Intervention 2: Control group: Placebo twice daily for 12 weeks.
|
Outcome Measures: |
Alanine aminotransferase. Timepoint: before intervention and after 12 weeks. Method of measurement: seum level.;Aspartate transaminase. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Gamma glutamyl transferase. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Alkaline phosphatase. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Triglycerides. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Total cholesterol. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Low density lipoprotein (LDL). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;High density lipoprotein (HDL). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fasting blood sugar. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fasting insulin. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Insulin resistance. Timepoint: before intervention and after 12 weeks. Method of measurement: 405??(insulin??glucose)=HOMA-IR ; Homeostatic model assessment.;Adiponectin. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fetuin A. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Fibroblast growth factor 21(FGF 21). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Total antioxidant capacity. Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;High sensitive C reactive protein (hs-CRP). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Interlukin-6(IL-6). Timepoint: before intervention and after 12 weeks. Method of measurement: serum level.;Weight. Timepoint: before intervention and after 12 weeks. Method of measurement: scale.;Waist circumference. Timepoint: before intervention and after 12 weeks. Method of measurement: waist circumference in CM.;Body mass index (BMI). Timepoint: before intervention and after 12 weeks. Method of measurement: Ratio of weight (kg) to second power (in meters).;Degree of hepatic steatosis. Timepoint: before intervention and after 12 weeks. Method of measurement: sonography.Systolic blood pressure. Timepoint: before intervention and after 12 weeks. Method of measurement: Blood pressure monitor.;Diastolic blood pressure. Timepoint: before intervention and after 12 weeks. Method of measurement: Blood pressure monitor.
|
Sponsor/Collaborators: |
Ahvaz University of Medical Sciences
|
Gender: |
All
|
Age: |
18 years65 years
|
Phases: |
Not applicable
|
Enrollment: |
50
|
Study Type: |
interventional
|
Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The present study is a simple randomized clinical trial on subjects with nonalcholic fatty liver. In this study, indiv
|
Start Date: |
04/12/2019
|
Completion Date: |
--
|
Results First Posted: |
--
|
Last Update Posted: |
17 December 2019
|
Locations: |
Iran (Islamic Republic of)
|
URL: |
http://en.irct.ir/trial/42739
|